The rise in Vaxart's stock price can be attributed to the positive sentiment surrounding the government contract and the successful capital raise, which are likely to support the company's vaccine development efforts. The CEO's resignation introduces some uncertainty, but the appointment of an interim CEO and the ongoing business activities seem to mitigate investor concerns in the short term.